ACT Capital Management’s Biohaven BHVN Stock Holding History

ACT Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,500	Closed	-$84.7K	–	59
2025 Q4	$84.7K	Buy	+7,500	New	+$92.9K	0.07%	52

Other funds holding BHVN

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $242M AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACT Capital Management's BHVN Position: Q1 2026 in Review

ACT Capital Management sold out of Biohaven (BHVN) in Q1 2026, closing a stake of 7,500 shares — an estimated $84.7K sold.

ACT Capital Management first reported a position in BHVN in Q4 2025 and held it in 1 quarter. The position peaked at $84.7K in Q4 2025. 277 funds tracked by Wall St. Rank hold BHVN as of Q1 2026.

ACT Capital Management reported no remaining Biohaven position as of Q1 2026 after selling out during the quarter.
ACT Capital Management sold 7,500 Biohaven shares in Q1 2026, an estimated $84.7K.
ACT Capital Management first reported a position in Biohaven in Q4 2025 and held it in 1 quarter.
ACT Capital Management's Biohaven position peaked at $84.7K in Q4 2025.
277 funds tracked by Wall St. Rank held Biohaven as of Q1 2026.

Based on ACT Capital Management's 13F filing for Q1 2026, filed 8 May 2026.